eFFECTOR Therapeutics (EFTRW) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends EFTRW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. eFFECTOR Therapeutics vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership. Does the media refer more to ATNFW or EFTRW? In the previous week, 180 Life Sciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for eFFECTOR Therapeutics. 180 Life Sciences' average media sentiment score of 1.89 beat eFFECTOR Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive eFFECTOR Therapeutics Neutral Does the MarketBeat Community prefer ATNFW or EFTRW? 180 Life Sciences and eFFECTOR Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AeFFECTOR TherapeuticsN/AN/A Which has preferable valuation & earnings, ATNFW or EFTRW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AeFFECTOR TherapeuticsN/AN/AN/AN/AN/A Is ATNFW or EFTRW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Summary180 Life Sciences beats eFFECTOR Therapeutics on 2 of the 2 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTRW vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$178.25M$5.62B$9.11BDividend YieldN/A3.64%5.36%3.98%P/E RatioN/A138.2689.5017.56Price / SalesN/A18,255.161,227.7282.80Price / CashN/A13.0144.3037.67Price / BookN/A8.965.124.73Net IncomeN/A-$20.89M$117.78M$224.51M eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTRWeFFECTOR TherapeuticsN/AN/AN/AN/A$0.00N/A0.0010ATNFW180 Life SciencesN/A$0.01+2.3%N/A+73.1%$0.00N/A0.007Gap DownSXTPW60 Degrees PharmaceuticalsN/A$0.02-33.3%N/A-73.3%$0.00$502,409.000.002News CoverageGap DownDRTSWAlpha Tau MedicalN/A$0.42+4.0%N/A+40.4%$0.00N/A0.0080Positive NewsGap UpWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-2.7%N/A-63.3%$0.00N/A0.0059Short Interest ↓Positive NewsBCTXWBriaCell TherapeuticsN/A$0.14+0.1%N/A-90.6%$0.00N/A0.008Short Interest ↑CDIOWCardio DiagnosticsN/A$0.07-0.3%N/A-52.7%$0.00$35,688.000.007Short Interest ↓Positive NewsGap UpCTCXWCarmellN/A$0.03+0.6%N/A-81.3%$0.00$32,839.000.0014Gap DownCELUWCelularityN/A$0.06-21.0%N/A+167.9%$0.00$48.20M0.00220High Trading VolumeCEROWCERo TherapeuticsN/A$0.01-33.3%N/AN/A$0.00N/A0.008Short Interest ↑ Related Companies and Tools Related Companies ATNFW Alternatives SXTPW Alternatives DRTSW Alternatives WENAW Alternatives APLMW Alternatives BCTXW Alternatives CDIOW Alternatives CTCXW Alternatives CELUW Alternatives CEROW Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EFTRW) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
